(Rac)-Rotigotine-d7 (hydrochloride)

(Rac)-Rotigotine-d7 (hydrochloride)

• UNSPSC Description: (Rac)-Rotigotine-d7 (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.
• Target Antigen: 5-HT Receptor; Adrenergic Receptor; Dopamine Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling;Others
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Endocrinology; Neurological Disease
• Solubility: 10 mM in DMSO
• Smiles: OC1=C2CCC(N(C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])CCC3=CC=CS3)CC2=CC=C1.Cl
• Molecular Weight: 358.98
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2] Fenu S, et al. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors. Eur J Pharmacol. 2016 Oct 5;788:183-91.|[3]Radad K, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP+ and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 2014;52(2):179-86.|[4]Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86.|[5]Wood M, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172(4):1124-35.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported